1. Home >
  2. M&A >
  3. Merger >
  4. United States >
  5. Michigan >
  6. Pharmacia Acquires The Upjohn Company

M&A Deal Summary

Pharmacia Acquires The Upjohn Company

On August 21, 1995, Pharmacia acquired life science company The Upjohn Company for 13.0B USD

Acquisition Highlights
  • This is Pharmacia’s 1st transaction in the Life Science sector.
  • This is Pharmacia’s largest (disclosed) transaction.
  • This is Pharmacia’s 1st transaction in the United States.
  • This is Pharmacia’s 1st transaction in Michigan.
Investment Fate
  • The Upjohn Company merged with another company in 2019.

M&A Deal Summary
Date 1995-08-21
Target The Upjohn Company
Sector Life Science
Buyer(s) Pharmacia
Deal Type Merger
Deal Value 13.0B USD

Target

The Upjohn Company

Kalamazoo, Michigan, United States
Upjohn seeks to leverage our portfolio, global experience and expertise to become the trusted partner of choice for all stakeholders committed to improving patient health. Upjohn focuses on relieving the burden of non-communicable diseases with trusted, quality medicines for every patient, everywhere. Upjohn brings together 20 of the industry's most trusted brands — products such as Lipitor, Norvasc, Lyrica and Viagra — with world-class medical, manufacturing and commercial expertise in more than 120 countries.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Pharmacia

Peapack, New Jersey, United States
Category Company
Founded 1901
Sector Life Science
Employees43,000
DESCRIPTION

Pharmacia Corp. a pharmaceutical and biotechnological company.

DEAL STATS #
Overall 1 of 2
Sector: Life Science M&A 1 of 2
Type: Merger M&A Deals 1 of 1
State: Michigan M&A 1 of 1
Country: United States M&A 1 of 2
Year: 1995 M&A 1 of 1
Size (of disclosed) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
1999-06-15 SUGEN

Redwood City, California, United States

SUGEN is a biotechnology company and worldwide leader in target-driven drug discovery and development for novel development-stage cancer therapies.

Buy $650M
Mergr

Solution for

Product

Company

Legal